Search results
Results from the WOW.Com Content Network
John Francis Crowley (born April 7, 1967) is the President and CEO of the Biotechnology Innovation Organization (BIO), the world’s largest biotechnology advocacy organization. [1] He served as the chairman and CEO of Amicus Therapeutics .
John Crowley (chairman emeritus) Bradley Campbell (president and COO) ... Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in ...
Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for ...
John Crowley and his wife Aileen are a Portland couple with two of their three children suffering from Pompe disease, a genetic anomaly that typically kills most children before their tenth birthdays. John, an advertising executive, contacts Robert Stonehill, a researcher in Nebraska who has done innovative research for an enzyme treatment for ...
Amicus Therapeutics saw its excellent 2012 performance cut in half today, as shares that had been up 70% for the year fell 45% in a single day. The fall came on news that the company's lead drug ...
Presenter: Tobias Willer, Amicus Therapeutics, Philadelphia, PA, U.S.A. Date and time: Wednesday, February 5, 3:30 – 5:30 p.m. PST; Location: Kiosk 31-A; Abstract Title: Long-term safety and efficacy of migalastat in adolescent patients with Fabry disease: Results from the ASPIRE study and open-label extension (Poster #283)
For premium support please call: 800-290-4726 more ways to reach us
In 2023, John Crowley, Executive Chairman of Amicus Therapeutics, was announced as BIO's next CEO. Crowley has a background in rare diseases and is credited with working on a drug to save his children's and all individuals with Pompe disease 's hearts.